Clinical Trials Browser

Phase 2 × Carcinoma, Renal Cell × Tyrosine Kinase Inhibitors × Clear all

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Phase 2 Completed

6 enrolled 11 charts

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT01649180 2021-08-12

PrE0801

Phase 2 Terminated

3 enrolled 7 charts

Carcinoma, Renal Cell, Kidney Neoplasms